|
Registration benefits include:
|
|
Access to CME/CE programs and certification
|
|
|
Free subscription to Biologic Bulletin newsletter
|
|
|
Reminders of new CME/CE activities
|
 REGISTER NOW
|
|
This Web site is supported by an
unrestricted educational grant from
Genentech, Inc.
|
|
|
|
 |
| |
PsoriasisTx.com is a free educational Web site designed to provide dermatologists, dermatology residents and fellows, dermatology nurses, and other dermatology professionals with the latest information about biologic therapies used to treat patients with moderate to severe psoriasis.
A variety of resources are available regarding treatments for psoriasis, including:
- General information about biologic therapies for psoriasis
- A wide selection of continuing medical education (CME) and continuing education (CE) programs accredited by Curatio CME Institute and other accrediting organizations. CME/CE opportunities include newsletters, webcasts, and more (free registration required)
- Exclusive Expert Practice articles from renowned faculty, including Alan Menter, MD; Mark G. Lebwohl, MD; Gerald G. Krueger, MD;
- An extensive meetings section, featuring detailed reports from recent dermatology meetings and a comprehensive listing of upcoming psoriasis-related meetings and symposia with links to event Web sites
- Access to selected journal articles on topics relating to the treatment of psoriasis
- A free subscription to our exclusive Biologic Bulletin newsletter (free registration required)
- And much more, including the Ask the Expert forum where our expert panel addresses your most difficult psoriasis cases
Thank you for visiting PsoriasisTx.com. We hope you find the information on new psoriasis treatment options useful in your efforts to keep apace with ongoing developments in biologic therapy and the ways biologic agents are changing treatment paradigms.
CLOSING THE GAP
|
Do you use biologic agents for patients with moderate to severe psoriasis?
|
|
WHAT'S NEW
NEW! - Clinically Challenging Cases - Expert Insights
CME SPOTLIGHT
|
|
The Impact of Weight on Long-Term Success in Psoriasis Treatment
CME-Certified Internet Enduring Activity
Archive of a CME Web teleconference series held June–August 2007
Release Date: October 2007
It is important for dermatologists to learn about the comorbidities commonly found in psoriasis patients who are obese, as well as the other weight-related factors that may affect the treatment outcome of psoriasis patients who receive biologic therapy. This CME activity explores the data on obesity and psoriasis and will further educate dermatologists on the effect of weight on successful treatment of this patient population.
Co-sponsored by the Dannemiller Memorial Educational Foundation and Curatio CME Institute
Support for this activity has been provided through an educational grant from Genentech, Inc.
Access this activity by clicking on Read More link below.
|
|
READ MORE
|
|
EXPERT PRACTICE HIGHLIGHT
|
 |
The Intersection of Genetics, Immunology, and Pathophysiology in Psoriasis
CME-Certified Expert Practice Article
An interview with Kenneth B. Gordon, MD
The genetics and pathophysiology of psoriasis are complex, and the exact biologic and genetic causes of this condition remain unknown. In this Expert Practice, Kenneth Gordon, MD, head of the Division of Dermatology at the NorthShore University HealthSystems, Evanston, Illinois, discusses the current scientific understanding of the pathophysiology of psoriasis, focusing on the genetics, immunobiology, and signaling pathways. Significant attention is given to explaining the impact of T-helper 17 (Th17) cell–specific pathways in the development of psoriasis.
|
| READ MORE |
|
MEETING SPOTLIGHT
|
|
Expert Insights on Biologic Agents and Psoriasis: Update From the American Academy of Dermatology (AAD) 66th Annual Meeting
CME-Certified Meeting Report
Edited by: Kenneth B. Gordon, MD
The American Academy of Dermatology held its 66th Annual Meeting February 1–5, 2008 in San Antonio, Texas. A variety of posters that focused on biologic agents used to treat psoriasis were presented, covering such topics as new agents in development, long-term efficacy, and the use of biologic agents in difficult-to-treat patients. In addition, the meeting featured presentations on other topics relating to psoriasis, such as quality-of-life issues, pathophysiology, and comorbidities. This article features highlights from posters presented at the meeting along with insights by Dr. Kenneth B. Gordon on the clinical implications of these studies.
|
| READ MORE |
|
|
|
|
|
